NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $31.00 price objective on the stock.

A number of other equities analysts have also issued reports on NRXP. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st.

NRx Pharmaceuticals Stock Up 24.6 %

NASDAQ:NRXP opened at $3.55 on Tuesday. The company has a market capitalization of $42.92 million, a PE ratio of -1.66 and a beta of 1.08. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $7.33. The stock’s 50 day moving average price is $2.32 and its 200 day moving average price is $1.92.

Insider Transactions at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt acquired 40,000 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were bought at an average cost of $1.17 per share, with a total value of $46,800.00. Following the purchase, the chairman now owns 84,634 shares of the company’s stock, valued at $99,021.78. This represents a 89.62 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 19.00% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.